

Literatur

Therapie von oralen Leukoplakien und malignen Mundschleimhautläsionen

Priv.-Doz. Dr. Dr. Matthias Kreppel, Dr. Tim Backhaus, Priv.-Doz. Dr. Dr. Martin Scheer, Priv.-Doz. Dr. Hans-Joachim Nickenig, Dr. Dr. Andrea Grandoch, Priv.-Doz. Dr. Dr. Daniel Rothamel, Univ. Prof. Dr. Dr. Joachim E. Zöller

Oralchirurgie Journal 3/15

1. Driemel O, Hertel K, Reichert TE, Kosmehl H. Aktuelle Klassifikation der Präkursorläsionen des oralen Plattenepithelkarzinoms - Prinzipien der WHO-Klassifikation 2005. *Mund Kiefer GesichtsChir* 2006;10:89-93.
2. Amagasa T, Yamashiro M, Uzawa N. Oral premalignant lesions: from a clinical perspective. *Int J Clin Oncol* 2011;16:5-14.
3. Neville BW, Day TA. Oral cancer and precancerous lesions. *CA: a cancer journal for clinicians* 2002;52:195-215.
4. Scully C, Bagan J, Hopper C, Epstein J. Oral cancer: Current and future diagnostic techniques. *American journal of dentistry* 2008;21:199-209.
5. Kreppel M, Rothamel D, Zöller J, Scheer M. Diagnostik und Therapie des oralen Plattenepithelkarzinoms. *Oralchirurgie Journal* 2012:6-15.
6. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. *J Oral Pathol Med* 2008;37:1-10.
7. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. *Oral oncology* 2009;45:317-23.
8. Reichart PA. Oral mucosal lesions in a representative cross-sectional study of aging Germans. *Community Dent Oral Epidemiol* 2000;28:398.
9. Gupta PC, Mehta FS, Daftary DK, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. *Community dentistry and oral epidemiology* 1980;8:283-333.
10. Pereira JS, Carvalho MV, Henriques AC, de Queiroz Camara TH, Miguel MC, Freitas RA. Epidemiology and correlation of the clinicopathologic features in oral epithelial dysplasia: analysis of 173 cases. *Ann Diagn Pathol* 2011;15:98-102.
11. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. *Oral Oncol* 2010;46:423-5.
12. Mehta FS, Pindborg JJ, Gupta PC, Daftary DK. Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. *Cancer* 1969;24:832-49.
13. Axell T. Occurrence of leukoplakia and some other oral white lesions among 20333 adult Swedish people. *Community Dent Oral Epidemiol* 1987;15:51.
14. Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort of Taiwan. *Br J Cancer* 2000;82:1871-4.
15. Vora HH, Trivedi TI, Shukla SN, Shah NG, Goswami JV, Shah PM. p53 Expression in leukoplakia and carcinoma of the oral tongue. *Int J Biol Markers* 2006;21:74-80.
16. Lim K, Moles DR, Downer MC, Speight PM. Opportunistic screening for oral cancer and precancer in general dental practice: results of a demonstration study. *Br Dent J* 2003;194:497-502.
17. van der Waal I, Reichart PA. Oral proliferative verrucous leukoplakia revisited. *Oral Oncol* 2008;44:719-21.
18. Wei L, Wang YF, Zhou HW, Peng S, Zhou ZT, Tang GY. Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 chinese patients. *BMC Cancer* 2010;10:685.

19. Gupta PC, Murti PR, Bhonsle RB. Epidemiology of cancer by tobacco products and the significance of TSNA. *Crit Rev Toxicol* 1996;26:183-98.
20. Maserejian NN, Joshipura KJ, Rosner BA, Giovannucci E, Zavras AI. Prospective study of alcohol consumption and risk of oral premalignant lesions in men. *Cancer Epidemiol Biomarkers Prev* 2006;15:774-81.
21. Saito T, Sugiura C, Hirai A, et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. *Int J Oral Maxillofac Surg* 2011;30:49-53.
22. Reichart PA. Identification of risk groups for oral precancer and cancer and preventive measures. *Clin Oral Invest* 2001;5:207-13.
23. Campisi G, Panzarella V, Giuliani M, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions. *Int J Oncol* 2007;30:813-23.
24. Lee SY, Cho NH, Choi EC, et al. Relevance of human papilloma virus (HPV) infection to carcinogenesis of oral tongue cancer. *Int J Oral Maxillofac Surg* 2010;39:678-83.
25. Reibel J. Prognosis of oral premalignant lesions: significance of clinical, histopathological and molecular biological characteristics. *Crit Rev Oral Biol Med* 2003;14:47-62.
26. Pindborg JJ, Renstrup G, Poulsen HE, Silverman S, Jr. Studies in Oral Leukoplakias. V. Clinical and Histologic Signs of Malignancy. *Acta odontologica Scandinavica* 1963;21:407-14.
27. Warnakulasuriya S, Newell W, Johnson W, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. *J Oral Pathol Med* 2007;36:575-80.
28. Warnakulasuriya S, Dietrich T, Bornstein MM, et al. Oral health risks of tobacco use and effects of cessation. *Int Dent J* 2010;60:7-30.
29. Kreppel M, Drebber U, Eich HT, et al. Combined-modality treatment in advanced oral squamous cell carcinoma with primary surgery followed by adjuvant radiochemotherapy. *Strahlenther Onkol* 2011;187:555-60.
30. Kreppel M, Eich HT, Kübler AC, Zöller JE, Scheer M. Prognostic Value of the 6th Edition of the UICC's TNM Classification and Stage Grouping for Oral Cancer. *J Surg Oncol* 2010;102:443-9.
31. Kowalski LP, Franco EL, Torloni H, et al. Lateness of diagnosis of oral and oropharyngeal carcinoma: factors related to the tumour, the patient and health professionals. *Eur J Cancer B Oral Oncol* 1994;30B:167-73.
32. Messadi D, Wilder-Smith P, Wolinsky P. Improving oral cancer survival: the role of dental providers. *Journal of the California Dental Association* 2009;37:789-98.
33. Scheer M, Neugebauer J, Derman A, Fuss J, Drebber U, Zoeller JE. Autofluorescence imaging of potentially malignant mucosa lesions. *Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics* 2011;111:568-77.
34. Remmerbach TW, Mathes SN, Weidenbach H, Hemprich A, Bocking A. [Noninvasive brush biopsy as an innovative tool for early detection of oral carcinomas]. *Mund-, Kiefer- und Gesichtschirurgie : MKG* 2004;8:229-36.
35. Vashisht N, Ravikiran A, Samatha Y, Rao PC, Naik R, Vashisht D. Chemiluminescence and Toluidine Blue as Diagnostic Tools for Detecting Early Stages of Oral Cancer: An invivo Study. *Journal of clinical and diagnostic research : JCDR* 2014;8:ZC35-8.
36. van der Waal I, AxÇll T. Oral Leukoplakia: A Proposal for uniform reporting. *Oral Oncol* 2002;38:521-6.
37. Kreppel M, Kreppel B, Drebber U, et al. Podoplanin expression in oral leukoplakia: prognostic value and and clinicopathologic implications. *Oral Dis* 2012;doi: 10.1111/j.1601-0825.2012.01927.x.
38. Kujan O, Khatib A, Oliver RJ, Roberts SA, Thakker N, Sloan P. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: An attempt to understand the sources of variation. *Oral Oncol* 2007;43:224-31.

39. Neid M, Tannapfel A. Intraepitheliale Plattenepithelneoplasie (WHO 2005). *HNO* 2009;57:181-8.
40. Gale N, Pilch BZ, Sidransky D, Westra WH, Califano J. Epithelial precursor lesions. *World Health Classification of tumours, Pathology and genetics of head and neck tumours*: IARC Press, Lyon; 2005:140-3.
41. Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N, Sloan P. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. *Oral Oncol* 2006;42:987-93.
42. Hellquist H, Cardesa A, Gale N, Kambic V, Michaels L. Criteria for grading in the Ljubljana classification of epithelial hyperplastic laryngeal lesions. A study by members of the Working Grouping on Epithelial Hyperplastic Laryngeal Lesions of the European Society of Pathology. *Histopathology* 1999;34:226-33.
43. Kambic V, Lenart I. Notre classification des hyperplasies de l'Épithélium du larynx au point de vue pronostic. *J Fr Otorhinolaryngol Audiophonol Chir Maxillofac* 1971;20:1145-50.
44. Gale N, Zidar N, Fischinger J, Kambic V. Clinical applicability of the Ljubljana classification of epithelial hyperplastic laryngeal lesions. *Clin Otolaryngol* 2000;25:227-32.
45. Mahajan M, Hazarey VK. An assessment of oral epithelial dysplasia using criteria of Smith and Pindborg's grading system and Ljubljana grading system in oral precancer lesions. *J Oral Maxillofac Pathol* 2004;8:73-81.
46. Amagasa T, Yamashiro M, Ishikawa H. Oral leukoplakia related to malignant transformation. *Oral Sci Int* 2006;3:45-55.
47. Cowan CG, Gregg TA, Napier SS, McKenna SM, Kee F. Potentially malignant oral lesions in Northern Ireland: A 20-year population-based perspective of malignant transformation. *Oral Dis* 2001;7:18-24.
48. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. *Oral oncology* 1998;34:270-5.
49. Speight PM, Farthing PM, Bouquot JE. The pathology of oral cancer and precancer. *Current Diagnostic Pathology* 1996;3:165-76.
50. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. *Oral oncology* 2006;42:461-74.
51. Kumar A, Cascarini L, McCaul JA, et al. How should we manage oral leukoplakia? *The British journal of oral & maxillofacial surgery* 2013;51:377-83.
52. Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ. Surgical treatment of premalignant lesions of the oral mucosa. *International journal of oral and maxillofacial surgery* 1987;16:656-64.
53. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. *Oral oncology* 2010;46:423-5.
54. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi F. Systematic review of randomized trials for the treatment of oral leukoplakia. *J Dent Educ* 2002;66:896-902.
55. Mehanna H, Rattay T, Smith J. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. *Head & neck* 2009;31:1600-9.
56. Gongloff RK, Gage AA. Cryosurgical treatment of oral lesions: report of cases. *Journal of the American Dental Association* 1983;106:47-51.
57. Ishii J, Fujita K, Komori T. Laser surgery as a treatment for oral leukoplakia. *Oral oncology* 2003;39:759-69.
58. Saito T, Sugiura C, Hirai A, et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. *International journal of oral and maxillofacial surgery* 2001;30:49-53.
59. Lim B, Smith A, Chandu A. Treatment of oral leukoplakia with carbon dioxide and potassium-titanyl-phosphate lasers: a comparison. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons* 2010;68:597-601.

60. Konopka K, Goslinski T. Photodynamic therapy in dentistry. *Journal of dental research* 2007;86:694-707.
61. Kvaal SI, Warloe T. Photodynamic treatment of oral lesions. *Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer* 2007;26:127-33.
62. Pietruska M, Sobaniec S, Bernaczyk P, et al. Clinical evaluation of photodynamic therapy efficacy in the treatment of oral leukoplakia. *Photodiagnosis and photodynamic therapy* 2014;11:34-40.
63. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, et al. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2009;15:6284-91.
64. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Concomitant leukoplakia in patients with oral squamous cell carcinoma. *Oral Dis* 1999;5:206-9.
65. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. *Oral oncology* 1997;33:231-6.
66. Byers RM, White D, Yue A. Squamous carcinoma of the oral cavity: choice of therapy. *Current problems in cancer* 1981;6:1-27.
67. Stich HF, Rosin MP, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. *International journal of cancer Journal international du cancer* 1988;42:195-9.
68. Sankaranarayanan R. Systemic and topical treatment of oral leukoplakia. *The British journal of oral & maxillofacial surgery* 1989;27:260-1.
69. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. *The New England journal of medicine* 1986;315:1501-5.
70. Halliwell B. The antioxidant paradox. *Lancet* 2000;355:1179-80.
71. Eberhardt M, Lee C, Liu R. Antioxidant activity of fresh apples. *Nature* 2000;405:903-4.
72. Talalay P. The importance of using scientific principles in the development of medical agents from plants. *Acad Med* 2001;76:238-47.
73. William WN, Jr., Papadimitrakopoulou VA. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials. *Cancer prevention research* 2013;6:375-8.
74. Kennedy A. Chemopreventive agents: protease inhibitors. *Pharmacol Ther* 1998;78:167-209.
75. Manzone H, Billings PC, Cummings WN, et al. Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* 1995;4:521-7.
76. Kennedy A, Billings P, Maki P, Newberne P. Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA. *Nutrition and cancer* 1993;19:191.
77. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL, Jr. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* 2000;9:43-7.
78. Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2000;6:4684-91.
79. Henning S, Niu Y, Lee N. Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement. *The American journal of clinical nutrition* 2004;80:1558-64.

80. Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. *Biochemical and biophysical research communications* 2000;275:328-34.
81. Hastak K, Agarwal M, Mukhtar H. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. *FASEB J* 2005;19:789-91.
82. Dionne KR, Warnakulasuriya S, Binti Zain R, Cheong SC. Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory. *International journal of cancer Journal international du cancer* 2014.
83. Schepman KP, van der Waal I. A proposal for a classification and staging system for oral leukoplakia: a preliminary study. *Eur J Cancer B Oral Oncol* 1995;32B:396-8.
84. Silverman S, Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. *Cancer* 1984;53:563-8.
85. Kreppel M, Eich HT, Brüggenolte C, et al. Preoperative vs. postoperative radiochemotherapy in patients with N2 squamous cell carcinoma of the oral cavity. *Oral Oncol* 2012;Epub ahead of print:DOI: 10.1016/j.oraloncology.2012.04.001.
86. Gupta PC. Leukoplakia and incidence of oral cancer. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology* 1989;18:17.
87. Tabor MP, Braakhuis BJM, van der Waal JE, et al. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. *J Pathol* 2003;199:354-60.
88. Lind PO. Malignant transformation in oral leukoplakia. *Scand J Dent Res* 1987;95:449-55.
89. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weakness and scope for improvement. *J Oral Pathol Med* 2008;37:127-33.
90. Bánóczy J. Follow-up studies in oral leukoplakia. *J Maxillofac Surg* 1977;5:69-75.
91. Pindborg JJ, Jolst O, Renstrup G, Roed-Petersen B. Studies in oral leukoplakia: a preliminary report on the period prevalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. *J Am Dent Assoc* 1968;76:767-71.
92. van der Waal I, Schepman KP, van der Meij EH. A modified classification and staging system for oral leukoplakia. *Oral Oncol* 2000;36:264-6.
93. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. *Clin Cancer Res* 2007;13:4035-41.
94. Lele S. Although leukoplakia responds to some treatments relapses and adverse effects are common. *Evid Based Dent* 2005;6:15-6.
95. Scheifele C, Reichart PA. Orale Leukoplakien beim manifesten Plattenepithelkarzinom. *Mund Kiefer GesichtsChir* 1998;2:326-30.
96. Prado SM, Cedrón JL, Rey RL, et al. Evaluation of COX-2, EGFR and p53 as biomarkers of non-dysplastic oral leukoplakias. *Exp Mol Pathol* 2010;89:197-203.
97. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008;26:354-60.
98. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. *Br J Cancer* 2007;96:1-5.
99. Madan R, Brandwein-Gensler M, Schlecht NF, et al. Differential tissue and subcellular expression of ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic significance for head and neck squamous cell carcinoma. *Head Neck* 2006;28:1018-27.
100. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. *J Cell Sci* 2006;119:4541-53.

101. Kreppel M, Drebber U, Wedemeyer I, et al. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. *Oral Oncol* 2011;doi:10.1016/j.oraloncology.2011.06.508.
102. Kreppel M, Scheer M, Drebber U, Ritter L, Zöller JE. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. *Virchows Arch* 2010;456:473-82.
103. Ang KK, Harris J, Wheeler R, et al. Human Papillomavirus and Survival in Patients with Oropharyngeal Cancer. *N Engl J Med* 2010;363:24-35.
104. Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancer. *Head Neck* 2007;29:779-92.
105. Nakahara y, shintani S, Mihara M. Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. *Cancer letters* 2000;160:3-8.
106. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2001;91:622-35.